← All trials
NCT05894135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Mar 31, 2025
- First posted
- Jun 8, 2023
- Last posted
- Jul 27, 2023
- Enrollment
- 540
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.